eNews April 13, 2021

The latest news affecting you and your customers… from the Independent Medical Specialty Dealers Association

How is COVID-19 affecting your business, your people, your customers? IMDA is a membership organization, and in times like these, we can all use some camaraderie. If you have a COVID story to share, advice to offer, or a warning to sound, send it to Mark Thill, IMDA’s communications director, at mdthill1913@gmail.com, with the subject line “IMDA COVID story.” We’ll compile them and send them back out to you.

Where the money goes

The medical device industry gave doctors consulting fees, lunches, lodging, and other incentive payments worth $904 million between 2014 and 2017, per a study appearing in Health Affairs, reports STAT. That’s $80 million more than the pharmaceutical industry gave to physicians over the same time period. Researchers found that the device industry gave most of its money to surgical specialists. Advamed, a trade association representing medical device makers, emphasized the important partnership between their manufacturers and doctors — helping to develop and refine medical devices and then to train their peers on how to use them. Pharmaceutical companies and medical device makers must report their payments to doctors in a government database called Open Payments.

Device for airway restrictions

Herzliya, Israel-based Respinova received 510(k) clearance from the U.S. Food and Drug Administration to market the Pulsehaler™, which is designed to facilitate the opening of airways and clearance of secretions in patients with respiratory diseases. Driven by an internal turbine and multi-frequency vibration disc, the device sends air pressure pulsations directly into the lung, making it easier to use for patients with airway restrictions, according to the company.

Arthritis drug fails to prevent mechanical ventilation

Eli Lilly and Co and Incyte Corp said their rheumatoid arthritis drug baricitinib failed to meet the main goal of preventing progression to mechanical ventilation in hospitalized COVID-19 patients under a late-stage study, reports Reuters. Patients receiving baricitinib were 2.7% less likely than those receiving standard of care to progress to ventilation, which was not statistically significant, the data showed. Baricitinib has been granted emergency use authorization by the FDA in combination with remdesivir for COVID-19 patients requiring supplemental oxygen. The study enrolled 1,525 hospitalized COVID-19 patients who received either baricitinib or placebo along with standard of care including corticosteroids and remdesivir.

AI detects potential lesions in colonoscopies

The U.S. Food and Drug Administration authorized marketing of the GI Genius™ from Dublin, Ireland-based Cosmo Pharmaceuticals, which uses artificial intelligence to assist clinicians in detecting lesions (such as polyps or suspected tumors) in the colon in real time during a colonoscopy. When the system identifies a potential lesion, it generates markers, which look like green squares and are accompanied by a short, low-volume sound, and superimposes them on the video from the endoscope camera. The GI Genius is designed to be compatible with many FDA-cleared standard video endoscopy systems.